Status:
COMPLETED
Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis
Lead Sponsor:
Federal University of São Paulo
Conditions:
Acute Coronary Syndrome
Platelet Function
Eligibility:
All Genders
Up to 75 years
Phase:
PHASE4
Brief Summary
Introduction: Platelet aggregation plays an important role in ischemic complications in patients undergoing to percutaneous coronary intervention (PCI). The addition of clopidogrel, as a second antip...
Eligibility Criteria
Inclusion
- less than 75 years
- sign the consent form
- Acute coronary syndrome with ST-segment elevation submitted to thrombolysis
Exclusion
- use of IIbIIIa inhibitor
- less than 60 kg
- history of stroke
- Patients with sick sinus syndrome, atrioventricular block second or third degree, not protected by pacemaker
- Chronic obstructive pulmonary disease
- Asthma
- Heart failure class III / IV
- renal replacement therapy
- Use of inducers (carbamazepine, phenytoin, phenobarbital, rifampicin and dexamethasone) or inhibitors (ketoconazole, itraconazole, ritonavir, saquinavir, clarithromycin) potent enzyme PYP3A
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02215993
Start Date
July 1 2013
End Date
October 1 2014
Last Update
May 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federal University of São Paulo
São Paulo, Brazil, 04024-002